Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBT (2016 - 2025)

Historic EBT for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$179.5 million.

  • Ultragenyx Pharmaceutical's EBT fell 3477.66% to -$179.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$576.7 million, marking a year-over-year decrease of 278.82%. This contributed to the annual value of -$567.6 million for FY2024, which is 671.82% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its EBT stood at -$179.5 million for Q3 2025, which was down 3477.66% from -$114.0 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year EBT high stood at -$72.8 million for Q3 2021, and its period low was -$238.8 million during Q3 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median EBT value was -$149.8 million (recorded in 2025), while the average stood at -$146.2 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 57401.87% in 2021, then soared by 3342.28% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's EBT stood at -$124.8 million in 2021, then dropped by 24.2% to -$155.0 million in 2022, then grew by 18.12% to -$126.9 million in 2023, then fell by 5.13% to -$133.4 million in 2024, then tumbled by 34.58% to -$179.5 million in 2025.
  • Its EBT stands at -$179.5 million for Q3 2025, versus -$114.0 million for Q2 2025 and -$149.8 million for Q1 2025.